{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:54:12Z","timestamp":1793760852737,"version":"4.6.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Allergan Norden AB"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Migraine is a common and incapacitating condition, with severe impact on the quality of life (QoL) of the afflicted and their families, and negative economic consequences through decreased workforce participation, reduced functional ability and elevated healthcare costs. This study aimed to describe the economic consequences of migraine in Sweden using cost of illness survey data and, based on this data, assess the cost-effectiveness of onabotulinumtoxinA (Botox) for the treatment of chronic migraine in Sweden and Norway.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A survey study was conducted in Swedish migraine patients, with questions on patient characteristics, headache frequency and severity, effect on daily activities and work, QoL, health resource utilization, and medication use. Resulting costs were estimated as annual averages over subgroups of average monthly headache days. Some results were used to inform a Markov cost-effectiveness chronic migraine model. The model was adapted to Sweden and Norway using local data. The analysis perspective was semi-societal. Results\u2019 robustness was tested using one-way, structural, and probabilistic sensitivity analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Results from the cost of illness analysis (<jats:italic>n<\/jats:italic>\u2009=\u2009454) indicated a clear correlation between decreased QoL and increased costs with increasing monthly headache days. Total annual costs ranged from EUR 6221 in patients with 0\u20134 headache days per month, to EUR 57,832 in patients with 25\u201331. Indirect costs made up the majority of costs, ranging from 82% of total costs in the 0\u20134 headache days group, to 91% in 25\u201331 headache days. The cost-effectiveness analyses indicated that in Sweden, Botox was associated with 0.223 additional QALYs at an additional cost of EUR 4126 compared to placebo, resulting in an incremental cost-effectiveness ratio (ICER) of EUR 18,506. In Norway, Botox was associated with 0.216 additional QALYs at an additional cost of EUR 4301 compared to placebo, resulting in an ICER of EUR 19,954.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In people with migraine, an increase in monthly headache days is clearly related to lower QoL and higher costs, indicating considerable potential costs-savings in reducing the number of headache days. The main cost driver for migraine is indirect costs. Botox reduces headache days and is a cost-effective treatment for chronic migraine in Sweden and Norway.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-020-01162-x","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T12:03:47Z","timestamp":1597233827000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway"],"prefix":"10.1186","volume":"21","author":[{"given":"Amanda","family":"Hansson-Hedblom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3629-5635","authenticated-orcid":false,"given":"Isabelle","family":"Axelsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joakim","family":"Tedroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Borgstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,12]]},"reference":[{"key":"1162_CR1","unstructured":"Dahl\u00f6f CH, JE. Migr\u00e4n 2019. Available from: https:\/\/www.internetmedicin.se\/page.aspx?id=251"},{"issue":"6","key":"1162_CR2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1468-2982.2004.00703.x","volume":"24","author":"M Linde","year":"2004","unstructured":"Linde M, Dahl\u00f6f C (2004) Attitudes and burden of disease among self-considered migraineurs\u2014a nation-wide population-based survey in Sweden. Cephalalgia 24(6):455\u2013465","journal-title":"Cephalalgia"},{"key":"1162_CR3","unstructured":"Norwegian health informatics (NHI). Migraines, overview. 2018. Available from: https:\/\/nhi.no\/sykdommer\/hjernenervesystem\/hodepiner\/migrene-oversikt\/."},{"issue":"6","key":"1162_CR4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/00043764-200206000-00013","volume":"44","author":"WN Burton","year":"2002","unstructured":"Burton WN, Conti DJ, Chen C-Y, Schultz AB, Edington DW (2002) The economic burden of lost productivity due to migraine headache: a specific worksite analysis. J Occup Environ Med 44(6):523\u2013529","journal-title":"J Occup Environ Med"},{"issue":"5","key":"1162_CR5","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1212\/WNL.55.5.624","volume":"55","author":"G Terwindt","year":"2000","unstructured":"Terwindt G, Ferrari M, Tijhuis M, Groenen S, Picavet H, Launer L (2000) The impact of migraine on quality of life in the general population: the GEM study. Neurology 55(5):624\u2013629","journal-title":"Neurology"},{"issue":"5","key":"1162_CR6","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0025-6196(11)60562-4","volume":"84","author":"WN Burton","year":"2009","unstructured":"Burton WN, Landy SH, Downs KE, Runken MC (2009) The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research. Mayo Clin Proc 84(5):436\u2013445","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"1162_CR7","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1111\/j.1526-4610.2008.01178.x","volume":"48","author":"A Molarius","year":"2008","unstructured":"Molarius A, Tegelberg \u00c5, \u00d6hrvik J (2008) Socio-economic factors, lifestyle, and headache disorders\u2014a population-based study in Sweden. Headache 48(10):1426\u20131437","journal-title":"Headache"},{"issue":"10","key":"1162_CR8","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1185\/030079904X3357","volume":"20","author":"AN Dueland","year":"2004","unstructured":"Dueland AN, Leira R, Burke TA, Hillyer EV, Bolge S (2004) The impact of migraine on work, family, and leisure among young women\u2013a multinational study. Curr Med Res Opin 20(10):1595\u20131604","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"1162_CR9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s10194-018-0907-6","volume":"19","author":"P Vo","year":"2018","unstructured":"Vo P, Fang J, Bilitou A, Laflamme AK, Gupta S (2018) Patients\u2019 perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom. J Headache Pain 19(1):82","journal-title":"J Headache Pain"},{"issue":"4","key":"1162_CR10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11136-010-9783-5","volume":"20","author":"R Xu","year":"2011","unstructured":"Xu R, Insinga RP, Golden W, Hu XH (2011) EuroQol (EQ-5D) health utility scores for patients with migraine. Qual Life Res 20(4):601\u2013608","journal-title":"Qual Life Res"},{"issue":"1","key":"1162_CR11","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s10194-019-1068-y","volume":"20","author":"A Negro","year":"2019","unstructured":"Negro A, Sciattella P, Rossi D, Guglielmetti M, Martelletti P, Mennini FS (2019) Cost of chronic and episodic migraine patients in continuous treatment for two years in a tertiary level headache Centre. J Headache Pain 20(1):120.","journal-title":"J Headache Pain"},{"issue":"5","key":"1162_CR12","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1468-1331.2011.03612.x","volume":"19","author":"M Linde","year":"2012","unstructured":"Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barr\u00e9 J, Katsarava Z et al (2012) The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol 19(5):703\u2013711","journal-title":"Eur J Neurol"},{"issue":"1","key":"1162_CR13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s10194-019-1015-y","volume":"20","author":"F Hjalte","year":"2019","unstructured":"Hjalte F, Olofsson S, Persson U, Linde M (2019) Burden and costs of migraine in a Swedish defined patient population\u2013a questionnaire-based study. J Headache Pain 20(1):65","journal-title":"J Headache Pain"},{"key":"1162_CR14","unstructured":"NEL Nevrologi. Retningslinjer for Botox-behandling ved kronisk migrene 2018. Available from: https:\/\/nevrologi.legehandboka.no\/handboken\/diverse\/retningslinjerveiledere\/retningslinjer-for-botox-behandling-ved-kronisk-migrene\/"},{"key":"1162_CR15","unstructured":"Norsk legemiddelh\u00e5ndbok. T6.2.1 Migrene 2018. Available from: https:\/\/www.legemiddelhandboka.no\/T6.2.1"},{"key":"1162_CR16","unstructured":"European Medicines Agency (EMA). Summary of Product Characteristics. BOTOX\u00ae 50 Allergan Units, Powder for Solution for Injection. European Medicines Agency (EMA). 2019"},{"issue":"9","key":"1162_CR17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1177\/0333102413485658","volume":"33","author":"Headache Classification Committee of the International Headache Society","year":"2013","unstructured":"Headache Classification Committee of the International Headache Society (2013) The international classification of headache disorders, (beta version). Cephalalgia 33(9):629\u2013808","journal-title":"Cephalalgia"},{"issue":"9","key":"1162_CR18","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/j.1526-4610.2011.01990.x","volume":"51","author":"SK Aurora","year":"2011","unstructured":"Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE et al (2011) OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache J Head Face Pain 51(9):1358\u20131373","journal-title":"Headache J Head Face Pain"},{"issue":"6","key":"1162_CR19","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","volume":"50","author":"DW Dodick","year":"2010","unstructured":"Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache J Head Face Pain 50(6):921\u2013936","journal-title":"Headache J Head Face Pain"},{"issue":"7","key":"1162_CR20","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","volume":"30","author":"S Aurora","year":"2010","unstructured":"Aurora S, Dodick DW, Turkel C, DeGryse R, Silberstein S, Lipton RB et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30(7):793\u2013803","journal-title":"Cephalalgia"},{"issue":"7","key":"1162_CR21","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","volume":"30","author":"H Diener","year":"2010","unstructured":"Diener H, Dodick DW, Aurora S, Turkel C, DeGryse R, Lipton RB et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30(7):804\u2013814","journal-title":"Cephalalgia"},{"issue":"1","key":"1162_CR22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s10194-018-0840-8","volume":"19","author":"AM Blumenfeld","year":"2018","unstructured":"Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Adams AM (2018) Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 19(1):13","journal-title":"J Headache Pain"},{"issue":"1","key":"1162_CR23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s10194-017-0802-6","volume":"18","author":"B Davies","year":"2017","unstructured":"Davies B, Gaul C, Martelletti P, Garc\u00eda-Monc\u00f3 JC, Brown S (2017) Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data. J Headache Pain 18(1):93","journal-title":"J Headache Pain"},{"issue":"7","key":"1162_CR24","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3111\/13696998.2013.802694","volume":"16","author":"AJ Batty","year":"2013","unstructured":"Batty AJ, Hansen RN, Bloudek LM, Varon SF, Hayward EJ, Pennington BW et al (2013) The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK. J Med Econ 16(7):877\u2013887","journal-title":"J Med Econ"},{"issue":"1","key":"1162_CR25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/13696998.2019.1675417","volume":"23","author":"G Hollier-Hann","year":"2020","unstructured":"Hollier-Hann G, Curry A, Onishchenko K, Akehurst R, Ahmed F, Davies B et al (2020) Updated cost-effectiveness analysis of onabotulinumtoxinA for the prevention of headache in adults with chronic migraine who have previously received three or more preventive treatments in the UK. J Med Econ 23(1):113\u2013123","journal-title":"J Med Econ"},{"issue":"1","key":"1162_CR26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10072-014-1741-5","volume":"35","author":"M Ruggeri","year":"2014","unstructured":"Ruggeri M (2014) The cost effectiveness of Botox in Italian patients with chronic migraine. Neurol Sci 35(1):45\u201347","journal-title":"Neurol Sci"},{"key":"1162_CR27","unstructured":"Huvudv\u00e4rksf\u00f6rbundet (\"the headache association\"). 2020 [Available from: http:\/\/www.huvudvarksforbundet.se\/"},{"issue":"5","key":"1162_CR28","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1212\/WNL.53.5.988","volume":"53","author":"WF Stewart","year":"1999","unstructured":"Stewart WF, Lipton RB, Whyte J, Dowson A, Kolodner K, Liberman J et al (1999) An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 53(5):988","journal-title":"Neurology"},{"key":"1162_CR29","unstructured":"FASS. Botox Allergan 2020 [Available from: https:\/\/www.fass.se\/LIF\/product?docType=30&specId&userType&nplId=20091117000049&scrollPosition=400"},{"key":"1162_CR30","unstructured":"Felleskatalogen. Botox Allergan 2019 [Available from: https:\/\/www.felleskatalogen.no\/medisin\/botox-allergan-547057"},{"key":"1162_CR31","unstructured":"S\u00f6dra sjukv\u00e5rdsregionen. Regionala priser och ers\u00e4ttningar f\u00f6r s\u00f6dra sjukv\u00e5rdsregionen 2019 [Available from: https:\/\/sodrasjukvardsregionen.se\/verksamhet\/avtal-priser\/regionala-priser-och-ersattningar-foregaende-ar\/"},{"key":"1162_CR32","unstructured":"Helsedirektoratet. Regelverk ISF 2018, DRG-liste somatikk 2018 [Available from: sieringsordninger\/innsatsstyrt-finansiering-isf-og-drg-systemet\/innsatsstyrt-finansiering-isf#regelverk-isf-2018"},{"key":"1162_CR33","unstructured":"Statistics Sweden. Genomsnittlig m\u00e5nadsl\u00f6n efter yrke 2018 [Available from: https:\/\/www.scb.se\/hitta-statistik\/statistik-efter-amne\/arbetsmarknad\/loner-och-arbetskostnader\/lonestrukturstatistik-landstingskommunal-sektor\/pong\/tabell-och-diagram\/genomsnittlig-manadslon-efter-yrke\/"},{"key":"1162_CR34","unstructured":"Legemiddelverket. Enhetskostnadsdatabase 2018 [Available from: https:\/\/legemiddelverket.no\/Documents\/Offentlig%20finansiering%20og%20pris\/Dokumentasjon%20til%20metodevurdering\/Enhetskostnadsdatabase_kostnader_0040618.pdf"},{"key":"1162_CR35","unstructured":"Norsk Legeforening. Normaltariff for avtalespesialister 2018\u20132019 [Available from: https:\/\/normaltariffen.legeforeningen.no\/pdf\/Normaltariff_2018.pdf"},{"key":"1162_CR36","unstructured":"Norsk legemiddelh\u00e5ndbok. L6.2.1 Selektive 5-HT1-reseptoragonister 2017 [Available from: https:\/\/www.legemiddelhandboka.no\/L6.2.1\/Legemidler_ved_nevrologiske_sykdommer#Lk-06-nevrol-1457"},{"key":"1162_CR37","unstructured":"Statistics Sweden. Medell\u00f6ner i Sverige 2018 [Available from: https:\/\/www.scb.se\/hitta-statistik\/sverige-i-siffror\/utbildning-jobb-och-pengar\/medelloner-i-sverige\/"},{"key":"1162_CR38","unstructured":"OECD. Hours worked - Total, Hours\/worker, 2018 or latest available 2018 [Available from: https:\/\/data.oecd.org\/emp\/hours-worked.htm"},{"key":"1162_CR39","unstructured":"Transportstyrelsen. Konsekvensutredning - \u00c4ndringsf\u00f6reskrift trafikregler f\u00f6r luftfart 2015 [2020-02-17]. Available from: https:\/\/transportstyrelsen.se\/globalassets\/global\/regler\/remisser\/luftfart\/konsekvensutredning-150611.pdf"},{"key":"1162_CR40","unstructured":"Hemfrid. Weekly cleaning and house chores 2020 [Available from: https:\/\/www.hemfrid.se\/?gclid=CjwKCAiA1rPyBRAREiwA1UIy8CeBqKyHX2ToIiM68FaRox2-vAS6D15Taoct5sb0EMcXt8zg3DPtNhoCx-MQAvD_BwE"},{"key":"1162_CR41","unstructured":"HomeMaid. Weekly cleaning and house chores 2020 [Available from: https:\/\/homemaid.se\/vara-tjanster\/hemstadning\/"},{"key":"1162_CR42","unstructured":"Statistics Sweden. Konsumentprisindex (1980=100), fastst\u00e4llda tal [Consumer Price Index] 2020 [Available from: https:\/\/www.scb.se\/hitta-statistik\/statistik-efter-amne\/priser-och-konsumtion\/konsumentprisindex\/konsumentprisindex-kpi\/pong\/tabell-och-diagram\/konsumentprisindex-kpi\/kpi-faststallda-tal-1980100\/"},{"key":"1162_CR43","unstructured":"Statistics Norway. Consumer price index 2020 [Available from: https:\/\/www.ssb.no\/en\/priser-og-prisindekser\/statistikker\/kpi\/maaned"},{"key":"1162_CR44","unstructured":"European Central Bank (ECB). Foreign Exchange reference rates - Swedish Krona (SEK), 2019 average 2019 [Available from: https:\/\/www.ecb.europa.eu\/stats\/policy_and_exchange_rates\/euro_reference_exchange_rates\/html\/eurofxref-graph-sek.en.html"},{"key":"1162_CR45","unstructured":"European Central Bank (ECB). Foreign Exchange reference rates - Norwegian Krone (NOK), 2019 average 2019 [Available from: https:\/\/www.ecb.europa.eu\/stats\/policy_and_exchange_rates\/euro_reference_exchange_rates\/html\/eurofxref-graph-nok.en.html"},{"key":"1162_CR46","unstructured":"Statistics Sweden. Tidsanv\u00e4ndningsunders\u00f6kningen (2010) - Hemarbete mer j\u00e4mlikt (The Swedish Time Use Survey (2010) - Men increase their share of unpaid housework) 2011 [Available from: https:\/\/www.scb.se\/en\/finding-statistics\/statistics-by-subject-area\/living-conditions\/living-conditions\/the-swedish-time-use-survey\/pong\/statistical-news\/the-swedish-time-use-survey-2010\/"},{"issue":"12","key":"1162_CR47","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.jval.2018.04.1828","volume":"21","author":"K Verbooy","year":"2018","unstructured":"Verbooy K, Hoefman R, Van Exel J, Brouwer W (2018) Time is money: investigating the value of leisure time and unpaid work. Value Health J 21(12):1428\u20131436","journal-title":"Value Health J"},{"key":"1162_CR48","unstructured":"The Dental and Pharmaceutical Benefits Agency (TLV). Underlag f\u00f6r beslut om subvention - Nyans\u00f6kan N\u00e4mnden f\u00f6r l\u00e4kemedelsf\u00f6rm\u00e5ner Ajovy (fremanezumab) Utv\u00e4rderad indikation 2019 [Available from: https:\/\/www.tlv.se\/download\/18.27af28ab16e5ee38db11d297\/1573647481854\/bes191024_underlag_ajovy.pdf"},{"key":"1162_CR49","unstructured":"The Norwegian Medicines Agency (NOMA). Hurtig metodevurdering ved forh\u00e5ndsgodkjent refusjon \u00a72 Aimovig (erenumab) til profylaktisk behandling av migrene. 2019 [Available from: https:\/\/legemiddelverket.no\/Documents\/Offentlig%20finansiering%20og%20pris\/Metodevurderinger\/A\/Aimovig_migrene_2019.pdf"},{"key":"1162_CR50","unstructured":"The Dental and Pharmaceutical Benefits Agency (TLV). \u00c4ndring i Tandv\u00e5rds- och l\u00e4kemedelsf\u00f6rm\u00e5nsverkets allm\u00e4nna r\u00e5d (TLVAR 2003:2) om ekonomiska utv\u00e4rderingar 2017 [Available from: https:\/\/www.tlv.se\/download\/18.467926b615d084471ac3230c\/1510316374332\/TLVAR_2017_1.pdf"},{"key":"1162_CR51","unstructured":"The Dental and Pharmaceutical Benefits Agency (TLV). H\u00e4lsoekonomi (in english: health economics) 2020 [Available from: https:\/\/www.tlv.se\/lakemedel\/halsoekonomi.html"},{"issue":"3","key":"1162_CR52","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jval.2011.12.007","volume":"15","author":"PJ Gillard","year":"2012","unstructured":"Gillard PJ, Devine B, Varon SF, Liu L, Sullivan SD (2012) Mapping from disease-specific measures to health-state utility values in individuals with migraine. Value Health J 15(3):485\u2013494","journal-title":"Value Health J"},{"issue":"3","key":"1162_CR53","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/0333102410381145","volume":"31","author":"AM Blumenfeld","year":"2011","unstructured":"Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A et al (2011) Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the international burden of migraine study (IBMS). Cephalalgia 31(3):301\u2013315","journal-title":"Cephalalgia"},{"issue":"3","key":"1162_CR54","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s11136-013-0537-z","volume":"23","author":"Y Feng","year":"2014","unstructured":"Feng Y, Parkin D, Devlin NJ (2014) Assessing the performance of the EQ-VAS in the NHS PROMs programme. Qual Life Res 23(3):977\u2013989","journal-title":"Qual Life Res"},{"key":"1162_CR55","unstructured":"Svensson M, Nilsson F (2016) TLV: s betalningsvilja f\u00f6r nya l\u00e4kemedel har analyserats: Kostnadseffektivitet och sjukdomens sv\u00e5righetsgrad avg\u00f6rande f\u00f6r subvention-Cancerl\u00e4kemedel f\u00e5r kosta mer. L\u00e4kartidningen 113(28\u201330). https:\/\/lakartidningen.se\/halsoekonomi\/2016\/07\/tlvs-betalningsvilja-for-nya-lakemedel-haranalyserats\/. Accessed 20 July 2020."},{"issue":"1","key":"1162_CR56","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s10194-019-0976-1","volume":"20","author":"F Ahmed","year":"2019","unstructured":"Ahmed F, Gaul C, Garcia-Monco JC, Sommer K, Martelletti P (2019) An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. J Headache Pain 20(1):26","journal-title":"J Headache Pain"},{"issue":"5","key":"1162_CR57","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10194-012-0460-7","volume":"13","author":"L Bloudek","year":"2012","unstructured":"Bloudek L, Stokes M, Buse D, Wilcox T, Lipton RB, Goadsby P et al (2012) Cost of healthcare for patients with migraine in five European countries: results from the international burden of migraine study (IBMS). J Headache Pain 13(5):361\u2013378","journal-title":"J Headache Pain"},{"key":"1162_CR58","unstructured":"Headaches Norway. Migraine. Available from: https:\/\/hodepinenorge.no\/hodepine\/migrene\/. Accessed 20 July 2020."},{"key":"1162_CR59","unstructured":"Hjalte F, Olofsson S, Persson U. Sjukdomsb\u00f6rdan vid migr\u00e4n i Sverige - en enk\u00e4tstudie av resurskonsumption och livskvalitet (eng: The burden of illness og migraine in Sweden - a questionnaire study of resource utilization and quality of life) - IHE Rapport 2018:2. The Swedish Institute for Health Economics (IHE). 2018(2018:4):82."}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01162-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-020-01162-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01162-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T23:05:54Z","timestamp":1628723154000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-020-01162-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,12]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1162"],"URL":"https:\/\/doi.org\/10.1186\/s10194-020-01162-x","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,12]]},"assertion":[{"value":"29 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval: Diarienr 2018\/1065\u201331\/5. Regionala etikpr\u00f6vningsn\u00e4mnden i Stockholm.Informed consent was obtained from all study participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All data analysed in this study were deidentified and results only presented on an aggregate level. Informed consent was obtained from all study participants prior to participation, and ethics approval was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"IA, FB and AH are employees of Quantify Research which was contracted and paid by Allergan Norden AB to conduct the study. The authors did not receive direct payment as a result of this work outside of their normal salary payments. LJ is an employee of Allergan Norden AB. JT has received compensation for lectures, educational efforts and consulting activities from Allergan Norden AB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}